Table 3 Most frequently prescribed treatment patterns
Variable | aNSCLC patients | Mutation positive aNSCLC patients | |||
|---|---|---|---|---|---|
N | Â | 1741 | Â | 122 | Â |
As 1 L treatment | Patients who started a 1 L treatment; N | 1672 |  | 117 |  |
% patients with at least 1 prescription | 21·23% | Pemetrexed | 20·51% | Erlotinib | |
7·72% | Pemetrexed +Unspecified | 11·11% | Pemetrexed | ||
7·36% | Bevacizumab + Pemetrexed | 6·84% | Pemetrexed + Cisplatin | ||
6·40% | Docetaxel | 6·84% | Pemetrexed + Unspecified | ||
5·62% | Bevacizumab | 5·98% | Bevacizumab | ||
As 2 L treatment | Patients who started a 2 L treatment; N | 635 |  | 96 |  |
% patients with at least 1 prescription | 25·83% | Erlotinib | 38·54% | Erlotinib | |
11·34% | Docetaxel | 7·29% | Pemetrexed | ||
8·03% | Pemetrexed | 7·29% | Gefitinib | ||
5·83% | Gemcitabine | 6·25% | Docetaxel + Nintedanib | ||
4·09% | Docetaxel + Nintedanib | 6·25% | Crizotinib | ||
As 3 L treatment | Patients who started a 3 L treatment; N | 242 |  | 55 |  |
% patients with at least 1 prescription | 20·25% | Erlotinib | 34·55% | Erlotinib | |
11·98% | Docetaxel | 12·73% | Docetaxel | ||
9·92% | Pemetrexed | 7·27% | Gemcitabine | ||
8·68% | Gemcitabine | 7·27% | Vinorelbine | ||
5·79% | Nivolumab | 5·45% | Pemetrexed | ||
As 3 + L treatment | Patients who started a 3 + L treatment; N | 90 |  | 30 |  |
% patients with at least 1 prescription | 12·22% | Nivolumab | 24·00% | Erlotinib | |
10·00% | Erlotinib | 16·00% | Pemetrexed | ||
8·89% | Nintedanib + Docetaxel | 12·00% | Docetaxel | ||
6·67% | Pemetrexed | 12·00% | Gemcitabine | ||
5·56% | Docetaxel | 8·00% | Nivolumab | ||